An observational study in Immune Thrombocytopenia, sponsored by Novartis Pharmaceuticals. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-10-15.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Purpura, Thrombocytopenic, Idiopathic by Novartis — 4 open to participants now, 7 under way, 2 of them phase 3. Purpura, Thrombocytopenic, Idiopathic · Novartis.
Among the 17 studies in Purpura, Thrombocytopenic, Idiopathic by Novartis, this one is one of 3 that started in 2026, is one of 3 observational ones, and was the 14th registered.
505 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 160 are open to participants now.
Browse Purpura, Thrombocytopenic, Idiopathic studies →4 of the 17 studies in Purpura, Thrombocytopenic, Idiopathic by Novartis are open now, in 2 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States
Ages 18+
Novartis Pharmaceuticals · Sites in United States
Ages 18+
Novartis Pharmaceuticals
Ages 5–17
By country, each count listing its studies:
Of the 104 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (47%) set no upper age limit and 43 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.
This study: 18 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 3 started in 2026.
This study's planned enrollment of 150 is above the median of 122 across 99 observational studies indexed under Purpura, Thrombocytopenic, Idiopathic.
Median enrollment 39 across the 12 interventional studies, 150 across the 3 observational. Of the 7 that completed or were terminated, 6 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,723 studies on the registry; 222 are open to participants now.
Of its 587 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
1 of the studies in Purpura, Thrombocytopenic, Idiopathic by Novartis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07786077Novartis PharmaceuticalsA Study of Patients' Preferences for Primary Immune Thrombocytopenia Treatment | 2026-12-15 |
Add it to your calendar (.ics) → With an account.
Among the 17 studies in Purpura, Thrombocytopenic, Idiopathic by Novartis, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to describe the treatment patterns and clinical outcomes of treatment with eltrombopag in primary immune thrombocytopenia (ITP) patients treated with prior corticosteroid therapy.
This study will use secondary data provided by health care professionals (HCPs) for a sample of primary ITP patients, and primary data from a structured HCP survey. Data will be collected from HCPs working in various clinical centers across the United States (US), United Kingdom (UK), and Germany.
Adult patients diagnosed with primary ITP who were treated with eltrombopag following corticosteroid treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
HCP inclusion criteria:
Patient-level inclusion criteria:
Exclusion criteria:
HCP exclusion criteria:
Patient-level exclusion criteria:
1. Diagnosis of Evans syndrome, secondary ITP, or non-immune thrombocytopenia.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adult patients diagnosed with primary ITP who initiated eltrombopag treatment between 01 January 2020 and 31 December 2024 following corticosteroid treatment.
Number and Percentage of Patients Achieving an Initial Platelet Response Within 12 Weeks of Start of Treatment
Initial platelet response is defined as a platelet count ≥50 × 10\^9/L.
Time frame: 12 weeks
Number and Percentage of Patients Achieving an Initial Complete Platelet Response Within 12 Weeks of Start of Treatment
Complete platelet response is defined as a platelet count of ≥100 × 10\^9/L.
Time frame: 12 weeks
Number and Percentage of Patients Achieving a Partial Platelet Response Within 12 Weeks of Start of Treatment
Partial platelet response is defined as a platelet count of ≥30 × 10\^9/L.
Time frame: 12 weeks
Number and Percentage of Patients With No or Suboptimal Platelet Response Within 12 Weeks of Start of Treatment
No or suboptimal platelet response is defined as a platelet count of \<30 × 10\^9/L.
Time frame: 12 weeks
Number and Percentage of Patients Achieving Clinically Meaningful Platelet Response Thresholds Within 12 Weeks of Start of Treatment
Clinically meaningful platelet response thresholds as indicated by a platelet count increase from a pretreatment value \<30 × 10\^9/L, and/or documentation of improvement in clinical symptoms such as bleeding.
Time frame: 12 weeks
Time to Platelet Response
Platelet response is defined as a platelet count ≥50 ×10\^9/L.
Time frame: Up to 4 years and 6 months after treatment initiation
Platelet Counts at Eltrombopag Treatment Initiation
Time frame: Day 1
Platelet Counts at Eltrombopag Treatment Discontinuation
Time frame: Up to 4 years and 6 months after treatment initiation
Number and Percentage of Patients With Bleeding Symptoms During Eltrombopag Treatment
Time frame: Up to 4 years and 6 months after treatment initiation
Duration Between ITP Diagnosis and Eltrombopag Treatment Initiation
Time frame: Up to 6 years prior to Day 1 of treatment
Number and Percentage of Patients With Concomitant Corticosteroid Treatment During Eltrombopag Treatment
Time frame: Up to 4 years and 6 months after treatment initiation
Number and Percentage of Patients With Concomitant Corticosteroid Treatment Withdrawn During Eltrombopag Treatment
Time frame: Up to 4 years and 6 months after treatment initiation
Time to Eltrombopag Treatment Discontinuation
Time frame: Up to 4 years and 6 months after treatment initiation
Number of Patients by Reason for Eltrombopag Initiation
Time frame: Up to 6 years prior to Day 1 of treatment
Number of Patients by Reason for Eltrombopag Discontinuation
Time frame: Up to 4 years and 6 months after treatment initiation
Baseline Demographics
Time frame: Up to 6 years prior to Day 1 of treatment
Number of Prior Corticosteroid Treatment Courses
Time frame: Up to 6 years prior to Day 1 of treatment
Duration of Prior Corticosteroid Treatment Courses
Time frame: Up to 6 years prior to Day 1 of treatment
Number of Patients by Comorbidities
Time frame: Up to 6 years prior to Day 1 of treatment
Number of Patients by HCP-reported Reason for Eltrombopag Initiation
Time frame: Up to 6 years prior to Day 1 of treatment
Number of Patients by HCP-reported Factors Influencing Selection of Eltrombopag as Second-line Treatment
Factors influencing selection include platelet count, bleeding symptoms, comorbidities, prior treatment response, ease of administration, safety profile, guideline recommendation, and other.
Time frame: Up to 6 years prior to Day 1 of treatment
Number of Patients by Location of Eltrombopag Prescription
Time frame: Up to 4 years and 6 months after treatment initiation
Number of Patients by Type of Provider of Eltrombopag Treatment Initiation
Providers include general practitioner, immunologist, hematologist, internal medicine specialist, and other.
Time frame: Day 1
Number of Patients Categorized by Typical Duration Between ITP Diagnosis and Eltrombopag Initiation as Reported by the HCP
Typical duration between diagnosis and treatment initiation categorized as \<3 months, 3-6 months, 6-12 months, \>12 months.
Time frame: Up to 6 years prior to Day 1 of treatment
Number of Patients by Corticosteroid Use During Eltrombopag Treatment as Reported by the HCP
Corticosteroid use categorized as never, rarely, sometimes, often, or always.
Time frame: Up to 4 years and 6 months after treatment initiation
Number of Patients by HCP-reported Indicators for Treatment Escalation or Discontinuation
Indicators for treatment escalation or discontinuation include lack of platelet response, bleeding symptoms, adverse events, stable response, patient preference, and other.
Time frame: Up to 4 years and 6 months after treatment initiation
Number of Patients by Common Reasons for Eltrombopag Discontinuation as Reported by the HCP
Time frame: Up to 4 years and 6 months after treatment initiation
Number of Patients by the HCP-reported Treatment Success With Eltrombopag
Treatment success categorized as rapid platelet increase, sustained response, bleeding control, minimal side effects, improved quality of life, and other.
Time frame: Up to 4 years and 6 months after treatment initiation
Number of Patients by Patient Characteristics Associated With Better Eltrombopag Response as Reported by the HCP
Patient characteristics include younger age, no comorbidities, early initiation post-diagnosis, prior corticosteroid response, and other
Time frame: Up to 4 years and 6 months after treatment initiation
Number of Patients by Patient Characteristics Associated With Poor Eltrombopag Response as Reported by the HCP
Patient characteristics include multiple comorbidities, delayed initiation, prior treatment failure, and other.
Time frame: Up to 4 years and 6 months after treatment initiation
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2026 (actual). Primary completion is estimated for Sep 2028, 27 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Purpura, Thrombocytopenic, Idiopathic →